Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new markets
Comunicato Precedente
Comunicato Successivo
"The two highest priorities on the company's agenda are accelerated sales in existing markets and partner agreements for new markets. Accordingly, we are strengthening our sales organization and planning to revamp our marketing strategy as well. The MDR certification we received last spring allows us to make new and stronger health claims. Over the past few weeks, the new MDR-labeled packages have started to appear on pharmacy shelves in Sweden, and new campaigns will soon follow.
It is thanks to our rights issue during the quarter that we can now strengthen our organization, increase our marketing activities and plan for more scientific studies. The fact that the rights issue was fully subscribed is a solid sign of strength, showing that many others share the view that there is incredible underlying potential in our enzyme technology, in ColdZyme and in Enzymatica as a company," said Claus Egstrand, CEO.
Significant events during the quarter
Significant events after the quarter
Other events during and after the quarter
The full report is available on: www.enzymatica.com/investors/financial-reports
This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on November 7, 2024.
For more information, please contact:
Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email:
[email protected]
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market.
For more information, please visit
www.enzymatica.com. Enzymatica's Certified Adviser is Carnegie Investment Bank AB (publ).
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/enzymatica-abs-interim-report-q32024-focus-on-developing-existing-and-new-markets-302298528.html
